|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2,380.00 - 2,465.20|
|52 Week Range||2,201.20 - 3,000.00|
|PE Ratio (TTM)||61.52|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||2,573.75|
GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.
GlaxoSmithKline (GSK) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.